نتائج البحث

Abstract CT001: CHRONOS-3: Randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL)

• Authors : Matasar, M.J.; Capra, M.; Özcan, M.

Subjects: Journal Article

• Source: Matasar, M.J., Capra, M., Özcan, M., Lv, F., Li, W., Yañez, E., Sapunarova, K., Lin, T., Jin, J., Jurczak, W., Hamed, A., Wang, M-C, Baker, R.

تفاصيل العنوان

CHRONOS‐3: Randomized phase III study of copanlisib plus rituximab/placebo in relapsed indolent Non-Hodgkin Lymphoma (INHL)

• Authors : Zinzani, P.L.; Capra, M.; Özcan, M.

Subjects: Journal Article

• Source: Zinzani, P.L., Capra, M., Özcan, M., Lv, F., Li, W., Yañez, E., Sapunarova, K., Lin, T., Jin, J., Jurczak, W., Hamed, A., Wang, M.C., Baker, R.

تفاصيل العنوان

CHRONOS‐3: Randomized phase III study of copanlisib plus rituximab/placebo in relapsed indolent Non-Hodgkin Lymphoma (INHL)

• Authors : Zinzani, P.L.; Capra, M.; Özcan, M.

Subjects: Journal Article

• Source: Zinzani, P.L., Capra, M., Özcan, M., Lv, F., Li, W., Yañez, E., Sapunarova, K., Lin, T., Jin, J., Jurczak, W., Hamed, A., Wang, M.C., Baker, R.

تفاصيل العنوان

Abstract CT001: CHRONOS-3: Randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL)

• Authors : Matasar, M.J.; Capra, M.; Özcan, M.

Subjects: Journal Article

• Source: Matasar, M.J., Capra, M., Özcan, M., Lv, F., Li, W., Yañez, E., Sapunarova, K., Lin, T., Jin, J., Jurczak, W., Hamed, A., Wang, M-C, Baker, R.

تفاصيل العنوان

Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas.

• Authors : Cheson, Bruce D; Cheson, Bruce D; O'Brien, Susan

Subjects: Humans; Lymphoma; Non-Hodgkin

• Source: Clinical lymphoma, myeloma & leukemia; vol 19, iss 3, 135-141; 2152-2650

تفاصيل العنوان

Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas.

• Authors : Cheson, Bruce D; Cheson, Bruce D; O'Brien, Susan

Subjects: Humans; Lymphoma; Non-Hodgkin

• Source: Clinical lymphoma, myeloma & leukemia; vol 19, iss 3, 135-141; 2152-2650

تفاصيل العنوان

Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib

• Authors : Krause, Guenter; Hassenrueck, Floyd; Hallek, Michael

Subjects: ddc:no; doc-type:article; publishedVersion

تفاصيل العنوان

Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib

• Authors : Krause, Guenter; Hassenrueck, Floyd; Hallek, Michael

Subjects: ddc:no; doc-type:article; publishedVersion

تفاصيل العنوان

Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib

• Authors : Krause,Günter; Hassenrück,Floyd; Hallek,Michael

Subjects: Drug Design, Development and Therapy; Review; info:eu-repo/semantics/article

تفاصيل العنوان

Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date

• Authors : Mensah,Felix; Blaize,Jean-Pierre; Bryan,Locke

Subjects: OncoTargets and Therapy; Review; info:eu-repo/semantics/article

تفاصيل العنوان